Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction
Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction
It is a randomized prospective controlled study of transcatheter renal denervation in
 patients with Heart Failure With Normal LV Ejection Fraction. The purpose of the study is to
 evaluate the safety and effectiveness of renal denervation in patients with Heart Failure
 With Normal LV Ejection Fraction, due to reduction in renal and systemic sympathetic
 activity.
Inclusion Criteria:

 -  Hypertension treated with at least 2 antihypertensive drugs;

 -  Heart failure with a normal LV ejection fraction;

 -  Left Ventricular Hypertrophy (LV mass index > 96 g/m2 in women and > 116 g/m2 in men);

 -  ≥ 18 years of age;

 Exclusion Criteria:

 -  Known secondary cause of hypertension

 -  Uncontrolled blood pressure (≥ 180x110mmHg)

 -  Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with
 balloon or stent

 -  Advanced renal insufficiency (estimated glomerular filtration rate (GFR) < 30
 ml/min/1.73 square meters)

 -  Diabetes Mellitus type 1

 -  Acute coronary syndrome or a cerebrovascular accident in the last 6 months

 -  Known other cause of respiratory dysfunction

 -  Previous LV systolic dysfunction (LVEF < 50%)

 -  Restrictive cardiomyopathy or Hypertrophic cardiomyopathy

 -  Significant valvar dysfunction

 -  Atrial flutter or atrial fibrillation

 -  Use of the oral anticoagulants

 -  Drug and Alcohol dependence